NCT04800822 2026-06-04PF-07284892 in Participants With Advanced Solid TumorsPfizerPhase 1 Terminated53 enrolled
NCT03678883 2026-04-039-ING-41 in Patients With Advanced CancersActuate Therapeutics Inc.Phase 2 Active not recruiting350 enrolled